Triple
T20301386
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | Vaxzevria COVID-19 vaccine |
E505486
|
entity |
| Predicate | hasAlternativeName |
P39
|
FINISHED |
| Object |
AZD1222
AZD1222 is the adenoviral vector-based COVID-19 vaccine developed by the University of Oxford and AstraZeneca for the prevention of SARS-CoV-2 infection.
|
E1423948
|
NE FINISHED |
How this triple was built (4 steps)
Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.
NER
Named-entity recognition
gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: AZD1222 | Statement: [Vaxzevria COVID-19 vaccine, hasAlternativeName, AZD1222]
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: AZD1222 Context triple: [Vaxzevria COVID-19 vaccine, hasAlternativeName, AZD1222]
-
A.
Imfinzi
Imfinzi is a prescription immunotherapy drug (durvalumab) developed by AstraZeneca, primarily used to treat certain types of lung and bladder cancers by helping the immune system attack cancer cells.
-
B.
Alecensa
Alecensa is a targeted cancer therapy (alectinib) primarily used to treat ALK-positive non-small cell lung cancer.
-
C.
Talycopa
Talycopa is a locality or area within the community of Llansamlet in Swansea, Wales.
-
D.
Zaltrap
Zaltrap is a cancer medication (brand name for aflibercept) used primarily in combination chemotherapy to treat metastatic colorectal cancer by inhibiting vascular endothelial growth factor (VEGF).
-
E.
Onpattro
Onpattro is an RNA interference (RNAi) therapeutic used to treat polyneuropathy in adults with hereditary transthyretin-mediated (hATTR) amyloidosis.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NEDg
Description generation
gpt-5.1
Instruction
Generate a one-sentence description of the target entity. You are given a context triple in the form (subject, predicate, object), where the object is the target entity. # Instructions Use the triple to infer relevant information about the entity. Describe the entity based on what is most defining, well-known. Avoid repeating the information from the triple, unless really essential. # Response Format Return only the sentence: "Description: [one-sentence description of the target entity]"
Input
Entity: AZD1222 Triple: [Vaxzevria COVID-19 vaccine, hasAlternativeName, AZD1222]
Generated description
AZD1222 is the adenoviral vector-based COVID-19 vaccine developed by the University of Oxford and AstraZeneca for the prevention of SARS-CoV-2 infection.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: AZD1222 Target entity description: AZD1222 is the adenoviral vector-based COVID-19 vaccine developed by the University of Oxford and AstraZeneca for the prevention of SARS-CoV-2 infection.
-
A.
Imfinzi
Imfinzi is a prescription immunotherapy drug (durvalumab) developed by AstraZeneca, primarily used to treat certain types of lung and bladder cancers by helping the immune system attack cancer cells.
-
B.
Alecensa
Alecensa is a targeted cancer therapy (alectinib) primarily used to treat ALK-positive non-small cell lung cancer.
-
C.
Talycopa
Talycopa is a locality or area within the community of Llansamlet in Swansea, Wales.
-
D.
Zaltrap
Zaltrap is a cancer medication (brand name for aflibercept) used primarily in combination chemotherapy to treat metastatic colorectal cancer by inhibiting vascular endothelial growth factor (VEGF).
-
E.
Onpattro
Onpattro is an RNA interference (RNAi) therapeutic used to treat polyneuropathy in adults with hereditary transthyretin-mediated (hATTR) amyloidosis.
- F. None of above. chosen
Provenance (5 batches)
The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.
| Step | Stage | Batch ID | Status | When |
|---|---|---|---|---|
| creating | Elicitation | batch_69e0b4b8ab648190906e18538c250148 |
completed | April 16, 2026, 10:06 a.m. |
| NER | Named-entity recognition | batch_69e6770c700c81909da247cef0d0f1eb |
completed | April 20, 2026, 6:57 p.m. |
| NED1 | Entity disambiguation (via context triple) | batch_6a08611762e481909ee2f41434c86aa5 |
completed | May 16, 2026, 12:20 p.m. |
| NEDg | Description generation | batch_6a0863506f4481909c106c49f6b71191 |
completed | May 16, 2026, 12:30 p.m. |
| NED2 | Entity disambiguation (via description) | batch_6a0863f4bb788190b6ef1fe57279badb |
completed | May 16, 2026, 12:32 p.m. |
Created at: April 16, 2026, 11:17 a.m.